Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
ATRC
$51.98
Atricure
$1.25
2.46%
ATRC
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus: ($0.25)
Revenue: $81.33 Mil
Tuesday
Nov 1
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Tuesday, August 2, 2022
AtriCure Reports Second Quarter 2022 Financial Results
What do you expect when ATRC reports earnings?
Beat
Meet
Miss
Where is ATRC's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$55.35
$54.13
$53.05
$51.83
Support
$50.75
$49.53
$48.45
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.
Peers
Stryker
3M
Boston Scientific
Abbott
Becton, Dickinson
Baxter International
Teleflex
ResMed
Waters
Integra LifeSciences Holdings
Expectations
›
Atricure